A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

Recruiting
99 years or below
All
Phase 3
10 participants needed
1 Location

Brief description of study

This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA). There is a paucity of data on long-term use of the combination of ADT and an antipsychotic drug.The trial will assess long-term benefit of continuation of adjunctive therapy in subjects who achieve a level of clinical stabilization.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Major depressive disorder, depression
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 831294

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.